New data from Eli Lilly says its daily, oral GLP-1 pill may help people who have obesity and people who have Type 2 diabetes ...

The latest results from a trial of a pill form popular GLP-1 medications offer enough information for the Eli Lilly to ...

Eli Lilly (LLY) stock is up as the firm's oral weight loss drug orforglipron hits key goals in another Phase 3 trial, ...

At current prices Novo Nordisk is a Strong Buy. It's good positioning in the promising weight loss segment, solid foundation ...

Eli Lilly's orforglipron could have a few advantages over a pill from Novo Nordisk, including a lack of dietary restrictions ...

Eli Lilly (LLY) announced the upcoming retirement of Anne White, a pivotal figure in its neuroscience division, and entered a ...

The company is the latest facing historic losses as pharmaceutical firms compete to develop a weight-loss pill.

Eli Lilly and Company has announced that Anne White, executive vice president and president of Lilly Neuroscience, will ...

Eli Lilly said on Tuesday its experimental GLP-1 pill helped overweight adults with type 2 diabetes shed 10.5% of body weight in a late-stage trial, after recent data from another study of the drug in ...

Eli Lilly & Co’s experimental obesity pill orforglipron helped patients lose 9.6% of their body weight in a late-stage trial, ...

Johnson & Johnson announces a $2 billion North Carolina manufacturing expansion as part of a broader U.S. onshore ...

Eli Lilly on Tuesday said its daily obesity pill succeeded in another late-stage trial, helping patients with obesity and Type 2 diabetes lose weight and lower their blood sugar levels. The company ...